Carlsmed, Inc. (CARL)
Carlsmed will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

Carlsmed is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).

The aprevo Technology Platform was designed to address the limitations of traditional spine fusion surgery and aims to optimize patient outcomes and reduce the need for revision surgeries.

By providing personalized surgical plans and interbody implants for custom vertebral fit that are powered by AI-enabled, outcomes-based algorithms, the aprevo Technology Platform supports surgeons in achieving proper spinal alignment for patients with degenerative disc disease, which can improve clinical outcomes and reduce the likelihood of revision surgeries.

We currently market the aprevo Technology Platform for lumbar spine fusion surgery, and we are further developing the aprevo Technology Platform for use in cervical spine fusion surgeries, which we expect to commercialize in 2026.

Carlsmed, Inc.
Country United States
Founded 2018
Industry Medical Devices
Sector Healthcare
Employees 100
CEO Michael Cordonnier

Contact Details

Address:
1800 Aston Ave, Suite 100
Carlsbad, CA 92008
United States
Phone (760) 766-1923
Website carlsmed.com

Stock Details

Ticker Symbol CARL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001794546
Employer ID 83-1081863
SIC Code 3841

Key Executives

Name Position
Michael (Mike) Cordonnier Chairman, Chief Executive Officer, President, and Co-Founder
Leonard (Leo) Greenstein Chief Financial Officer, Treasurer
William (Scott) Durall Chief Commercial Officer
Niall Casey Co-Founder, Chief Intellectual Property Officer, Secretary, Director
Jonathan (Jon) Root, M.D. Director
Robert Mittendorff, M.D. Director
Philip (Phil) Young Director
Kevin Sidow Director
Kevin O’Boyle Director

Latest SEC Filings

Date Type Title
Jun 26, 2025 S-1 General form for registration of securities under the Securities Act of 1933
May 30, 2025 DRS/A [Amend] [Cover] Draft Registration Statement
Apr 24, 2025 DRS [Cover] Draft Registration Statement
Feb 7, 2025 D/A Filing
Mar 21, 2024 D Notice of Exempt Offering of Securities
Apr 27, 2022 D Notice of Exempt Offering of Securities
Dec 17, 2020 D Notice of Exempt Offering of Securities
May 15, 2020 D/A Filing
Nov 19, 2019 D Notice of Exempt Offering of Securities